Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181124 | 0.74 | TLR8 (0.34) | LMNAALDH1A1GAAKMT2AMAPT | |
| SCHEMBL148439 | 0.73 | — | — | |
| SCHEMBL29987888 | 0.73 | — | — | |
| SCHEMBL16877109 | 0.72 | GAA (0.33) | LMNAALDH1A1GAAKMT2AMAPT | |
| SCHEMBL5576942 | 0.71 | ALDH1A1 (0.44) | LMNAALDH1A1GAAKMT2AMAPT | |
| SCHEMBL12636463 | 0.71 | PARP1 (0.47) | LMNAALDH1A1GAAKMT2AMAPT | |
| SCHEMBL164463 | 0.70 | — | — | |
| SCHEMBL12892255 | 0.70 | — | — | |
| SCHEMBL1131654 | 0.70 | — | — | |
| SCHEMBL29693610 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111356687-B | Pyrimidine-containing tri-substituted imidazole compound and application thereof | 广州必贝特医药技术有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020192302-A1 | PYRIMIDINE-CONTAINING TRI-SUBSTITUTED IMIDAZOLE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药技术有限公司 | 2020-10-01 | — | — | WO | disclosed |
| CN-111356687-A | Pyrimidine-containing tri-substituted imidazole compound and application thereof | 广州必贝特医药技术有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2250150-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| EP-1423384-B1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1423384-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-02 | — | — | EP | disclosed |
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
| EP-1307454-A1 | DERIVATIVES OF VARIOLIN B | Universidad de Barcelona (ES) | 2003-05-07 | — | — | EP | disclosed |
| WO-2003022840-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002012240-A1 | DERIVATIVES OF VARIOLIN B | UNIVERSIDAD DE BARCELONA (ES) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | LMNA 2104/4885ALDH1A1 2937/4885GAA 3926/4885 |
| US-20080033001-A1 | Derivatives of Variolin B | ARG2, SDHB, OAT | LMNA 2521/4885ALDH1A1 1460/4885GAA 4321/4885 |
| US-20040058939-A1 | Derivatives of variolin b | HNRNPA2B1, HNRNPAB, SYNCRIP | LMNA 2548/4885ALDH1A1 1470/4885GAA 4183/4885 |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | LMNA 3402/4885ALDH1A1 742/4885GAA 4594/4885 |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | LMNA 1627/4885ALDH1A1 4032/4885GAA 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.